Table 1 Clinical characteristics for the high grade serous ovarian cancer patient cohort (n = 20) with paired pre- and post-neoadjuvant chemotherapy (NACT) treated tumor samples analyzed by proteomics

Age at diagnosis

  < 50 years old

4 (0.20)

 50–59 years old

9 (0.45)

 60–69 years old

4 (0.20)

 70–79 years old

3 (0.15)

Race and ethnicity

 White

3 (0.15)

 Black

4 (0.20)

 Hispanic

13 (0.65)

Stage

 III NOS

3 (0.15)

 IIIB

1 (0.05)

 IIIC

5 (0.25)

 IV NOS

3 (0.15)

 IVA

3 (0.15)

 IVB

5 (0.25)

Residual disease

 R0

14 (0.70)

 R1

6 (0.30)

Disease distribution^a

 Moderate

8 (0.40)

 High

12 (0.60)

Cycles of NACT paclitaxel and carboplatin

 3

6 (0.30)

 4

13 (0.65)

 6

1 (0.05)

Recurrence^b

 Yes

16 (0.80)

 No

4 (0.20)